Thursday, 25 Apr 2019

You are here

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Reuters:Trump assails high drug prices, avoids direct hit on industry  https://reut.rs/2IBaFiY

Bloomber: Trump's Unimpressive Plan to Lower Drug Prices  https://bloom.bg/2I8tkmO

Financial Times: Trump blames foreign countries for high drug prices  https://on.ft.com/2IdPe4c

NY Times: 6 Takeaways From Trump’s Plans to Try to Lower Drug Prices https://nyti.ms/2IEieFS

          Trump’s Plan to Lower Drug Prices Diverges From Campaign Promise  https://nyti.ms/2wyN65D

           Trump to Drop Call for Medicare to Negotiate Lower Drug Prices  https://nyti.ms/2wAmGR1

Wall St. Journal: Trump’s Plan to Cut Drug Prices Leaves Industry Relieved https://on.wsj.com/2IDeAf6

NPR:  Trump Drug Pricing 'Blueprint' Could Take Years To Build  https://n.pr/2IyMRw5

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Timing of Shoulder Injections Impacts Surgical Infection Risk

A study of patients undergoing arthroscopic rotator cuff repair shows that corticosteroid injections in the month prior to surgery are associated with a significantly increased risk of surgical site infection.

Dietary Supplements Fail to Reduce Mortality Risks

An NIH funded prospective study has shown that the use of daily dietary supplements was not associated with a subsequent lowering of mortality risk.

An Autoimmune Diagnosis Alters Perceptions of Pregnancy and Lactation

A study from UT Southwestern and the Baylor Research Institute examined the preceptions and practices of women with autoimmune or inflammatory rheumatic diseases (AIRD) noting that an AIRD diagnosis changed most womens future hopes and plans regarding pregnancy and lactation.

ACR Position Statements on Drug Pricing and Step Therapy

The American College of Rheumatology Committee on Rheumatologic Care has released new drug pricing and step therapy position statements that they hope legislators will consider as they continue to explore policy and regulatory options to make drugs more affordable and accessible.  

CRA Position Statement on Medical Cannabis Use

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.